<!DOCTYPE html>
<html>
<head>
	<title>MRCG Clinical Guidelines</title>
	<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=2.0, user-scalable=1">
  
	<<meta name=Generator content="Microsoft Word 14 (filtered)">
	<link rel="stylesheet" href="jquery.mobile-1.4.5.min.css" />
	<script src="jquery-1.11.1.min.js"></script>
	<script src="jquery.mobile-1.4.5.min.js"></script>
	<script type="text/javascript" src="cordova.js"></script>      
	<style>
	.show {display: block;}
  .tablist-left {
    width: 25%;
    display: inline-block;
  }
  .tablist-content {
    width: 60%;
    display: inline-block;
    vertical-align: top;
    margin-left: 5%;
    }
    body {
  font-family: Arial, Helvetica, sans-serif;
  font-size: 20px;
}
.footer-button-left,
.footer-button-right {
    position: absolute;
    margin: 0;
    top: auto;
    bottom: 0.24em;
}
.footer-button-left {
    left: 0.4em;
}
.footer-button-right {
    right: 0.4em;
}
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Lucida Grande";}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:18.0pt;
	margin-left:0cm;
	font-size:14.0pt;
	font-family:"Arial","sans-serif";}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:12.0pt;
	margin-left:0cm;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0cm;
	margin-bottom:9.0pt;
	margin-left:0cm;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";
	text-decoration:underline;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:2.0pt;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:0cm;
	margin-bottom:.0001pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	color:#365F91;
	font-weight:normal;
	font-style:italic;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0cm;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Arial","sans-serif";}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	font-size:9.0pt;
	font-family:"Lucida Grande","sans-serif";}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:36.0pt;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:0cm;
	margin-left:36.0pt;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:36.0pt;
	font-size:11.0pt;
	font-family:"Arial","sans-serif";}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Arial","sans-serif";
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Arial","sans-serif";
	font-weight:bold;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Lucida Grande","sans-serif";}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Arial","sans-serif";
	font-weight:bold;
	text-decoration:underline;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Arial","sans-serif";}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Calibri","sans-serif";
	color:#365F91;
	font-style:italic;}
span.UnresolvedMention1
	{mso-style-name:"Unresolved Mention1";
	color:#605E5C;
	background:#E1DFDD;}
.MsoChpDefault
	{font-size:10.0pt;
	font-family:"Tahoma","sans-serif";}
 /* Page Definitions */
 @page WordSection1
	{size:612.0pt 792.0pt;
	margin:72.0pt 90.0pt 72.0pt 90.0pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0cm;}
ul
	{margin-bottom:0cm;}
-->
   .tableCont {
    overflow: auto;
    -webkit-overflow-scrolling: touch;
}
  </style>
  	  	<script>
		$(function(){
			$( "[data-role='header'], [data-role='footer']" ).toolbar();
			$('input[data-type="search"]').val("");			
		});
		// When the user scrolls down 20px from the top of the document, show the button
		window.onscroll = function() {scrollFunction()};
		function scrollFunction() {
		  if (document.body.scrollTop > 20 || document.documentElement.scrollTop > 20) {
			document.getElementById("myBtn").style.display = "block";
		  } else {
			document.getElementById("myBtn").style.display = "none";
		  }
		}
		// When the user clicks on the button, scroll to the top of the document
		function topFunction() {
		  document.body.scrollTop = 0; // For Safari
		  document.documentElement.scrollTop = 0; // For Chrome, Firefox, IE and Opera
		}
	</script>

</head>
<body lang=EN-GB link=blue vlink=purple>
	<div data-role="header" data-tap-toggle="false" data-id="persistent-header" data-position="fixed" data-theme="a">
		<h2 style="font-size:0.75em;"><br><br><br>MRCG<br>Clinical Guidelines</h2>
		<a data-rel="back" class="ui-btn ui-corner-all ui-btn-inline ui-mini header-button-left ui-btn-icon-left ui-icon-carat-l">Back</a>
		<a href="#leftpanel1" class="ui-btn ui-shadow ui-corner-all ui-btn-inline ui-mini header-button-left ui-icon-info ui-btn-icon-notext">About this app</a>
		<a href="#popupNested"  data-rel="popup" class="ui-btn ui-corner-all ui-shadow ui-btn-inline ui-icon-bars ui-btn-icon-right ui-btn-b header-button-right" data-transition="pop">Choose a guideline...</a>
		<div data-role="popup" id="popupNested" data-theme="a"><ul data-role="listview" data-filter="true"data-filter-placeholder="Type to search names..." data-inset="true">
			<li><a href="Acute_kidney_injury_MeG-CLS-071.html">Acute kidney injury</a></li>
			<li><a href="Acute_rheumatic_fever__MeG-CLS-048.html">Acute rheumatic fever </a></li>
			<li><a href="Animal_bites_MeG-CLS-049.html">Animal bites</a></li>
			<li><a href="Asthma_MeG-CLS-001.html">Asthma</a></li>
			<li><a href="Bone_and_joint_infections_guidelines_MeG-CLS-050.html">Bone and joint infections guidelines</a></li>
			<li><a href="Cellulitis_MeG-CLS-051.html">Cellulitis</a></li>
			<li><a href="Chest_pain_and_Acute_Coronary_Syndrome_MeG-CLS-052.html">Chest pain and Acute Coronary Syndrome</a></li>
			<li><a href="Chronic_kidney_disease_MeG-CLS-053.html">Chronic kidney disease</a></li>
			<li><a href="Congenital_heart_disease_MeG-CLS-039.html">Congenital heart disease</a></li>
			<li><a href="Constipation_MeG-CLS-003.html">Constipation</a></li>
			<li><a href="COPD_MeG-CLS-032.html">Chronic Obstructive Pulmonary Disease</a></li>
			<li><a href="Croup_MeG-CLS-059.html">Croup</a></li>
			<li><a href="Deep_venous_thombosis_and_pulmonary_embolism_MeG-CLS-055.html">Deep venous thombosis and pulmonary embolism</a></li>
			<li><a href="Depression_MeG-CLS-075.html">Depression</a></li>
			<li><a href="Developmental_delay_MeG-CLS-054.html">Developmental delay</a></li>
			<li><a href="Diabetes_Mellitus_MeG-CLS-004.html">Diabetes Mellitus</a></li>
			<li><a href="DKA_MeG-CLS-021.html">Diabetic ketoacidosis</a></li>
			<li><a href="Dyspepsia_MeG-CLS-034.html">Dyspepsia</a></li>
			<li><a href="Ear_pain_MeG-CLS-070.html">Ear pain</a></li>
			<li><a href="Epiglottitis_MeG-CLS-063.html">Epiglottitis</a></li>
			<li><a href="Epilepsy_MeG-CLS-056.html">Epilepsy</a></li>
			<li><a href="Fungal_Skin_Infections_MeG-CLS-057.html">Fungal Skin Infections</a></li>
			<li><a href="Gastroenteritis_MeG-CLS-033.html">Gastroenteritis</a></li>
			<li><a href="General_Body_Pain_MeG-CLS-007.html">General Body Pain</a></li>
			<li><a href="Headache_MeG-CLS-045.html">Headache</a></li>
			<li><a href="Heart_failure_adults_MeG-CLS-040.html">Heart failure adults</a></li>
			<li><a href="HHS_MeG-CLS-046.html">Hyperosmolar Hyperglycaemic State</a></li>
			<li><a href="HIV_MeG-CLS-035.html">HIV</a></li>
			<li><a href="Hypertension_MeG-CLS-010.html">Hypertension</a></li>
			<li><a href="Hyperthyroidism_and_goitre_MeG-CLS-027.html">Hyperthyroidism and goitre</a></li>
			<li><a href="Hypocalcaemia_and_hypercalcaemia_MeG-CLS-074.html">Hypocalcaemia and hypercalcaemia</a></li>
			<li><a href="Hypokalaemia_hyperkalaemia_hypermagnesaemia_MeG-CLS-073.html">Hypokalaemia, hyperkalaemia, hypermagnesaemia</a></li>
			<li><a href="Hyponatraemia_and_hypernatraemia_MeG-CLS-072.html">Hyponatraemia and hypernatraemia</a></li>
			<li><a href="Hypothyroidism_MeG-CLS-036.html">Hypothyroidism</a></li>
			<li><a href="Infective_Endocarditis_MeG-CLS-058.html">Infective Endocarditis</a></li>
			<li><a href="Inflammatory_arthritis_and_connective_tissue_disease_MeG-CLS-041.html">Inflammatory arthritis and connective tissue disease</a></li>
			<li><a href="Intestinal_helminths_MeG-CLS-009.html">Intestinal helminths</a></li>
			<li><a href="Liver_disease_MeG-CLS-031.html">Liver disease</a></li>
			<li><a href="Lower_back_pain_MeG-CLS-022.html">Lower back pain</a></li>
			<li><a href="LRI_MeG-CLS-011.html">Lower Respiratory Infections</a></li>
			<li><a href="Malaria_MeG-CLS-012.html">Malaria</a></li>
			<li><a href="Malnutrition_MeG-CLS-037.html">Malnutrition</a></li>
			<li><a href="Meningitis_MeG-CLS-028.html">Meningitis</a></li>
			<li><a href="Neonatal_jaundice_MeG-CLS-060.html">Neonatal jaundice</a></li>
			<li><a href="Nephrotic_Syndrome_MeG-CLS-061.html">Nephrotic Syndrome</a></li>
			<li><a href="Osteoarthritis_MeG-CLS-042.html">Osteoarthritis</a></li>
			<li><a href="Otitis_media_MeG-CLS-023.html">Otitis media</a></li>
			<li><a href="Palliative_Care_MeG-CLS-064.html">Palliative Care</a></li>
			<li><a href="Rectal_prolapse_MeG-CLS-015.html">Rectal prolapse</a></li>
			<li><a href="Rheumatic_heart_disease_MeG-CLS-065.html">Rheumatic heart disease</a></li>
			<li><a href="Scabies_MeG-CLS-066.html">Scabies</a></li>
			<li><a href="Sepsis_in_adults_MeG-CLS-043.html">Sepsis in adults</a></li>
			<li><a href="Sinusitis_MeG-CLS-062.html">Sinusitis</a></li>
			<li><a href="Stevens-Johnsons_syndrome_MeG-CLS-067.html">Stevens-Johnsons syndrome</a></li>
			<li><a href="STI_MeG-CLS-038.html">Sexually Transmitted Infections</a></li>
			<li><a href="Stroke_MeG-CLS-020.html">Stroke</a></li>
			<li><a href="TB_MeG-CLS-044.html">TB</a></li>
			<li><a href="Tonsillitis_and_pharyngitis_MeG-CLS-024.html">Tonsillitis and pharyngitis</a></li>
			<li><a href="Trauma_MeG-CLS-068.html">Trauma</a></li>
			<li><a href="Upper_respiratory_tract_infections_MeG-CLS-018.html">Upper respiratory tract infections</a></li>
			<li><a href="UTI_MeG-CLS-019.html">Urinary tract infections</a></li>
</ul>
	  </div>
	  </div>
	 
    </div><!-- /header -->
<div data-role="page">
	<div role="main" class="ui-content">
<div class=WordSection1>
<h1 style='margin-bottom:12.0pt'><span lang=EN-US>Hypertension</span></h1>
<h2><i><span lang=EN-US>Executive summary</span></i></h2>
<h2><span lang=EN-US>Introduction</span></h2>
<p class=MsoNormal><span lang=EN-US>Hypertension means elevated (arterial)
blood pressure. It is the leading modifiable risk factor for death and
disability worldwide. Starting from 115/75 mmHg, every 20 mmHg increase in
systolic blood pressure or 10 mmHg rise in diastolic blood pressure doubles the
risk of death from cardiovascular disease.</span></p>
<p class=MsoNormal><span lang=EN-US>Between 18 to 32% of adults in The Gambia
are hypertensive. Over 90% of hypertension is of unknown cause (essential/primary/
idiopathic) with risk factors including increasing age, male sex, Black race
and family history of hypertension. Most cases of secondary hypertension result
from renal disease. </span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Target users</span></h3>
<p class=MsoListParagraphCxSpFirst style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Nurses</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Doctors</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Target area
of use </span></h3>
<p class=MsoListParagraphCxSpFirst style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Gate clinic</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:39.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Outpatient department</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Key areas of
focus / New additions / Changes </span></h3>
<p class=MsoNormal><span lang=EN-US>This guideline addresses the diagnosis and
treatment of hypertension in the CSD.</span></p>
<p class=MsoNormal><span lang=EN-US>The evaluation of patients with
hypertension is aimed at identifying possible underlying causes, assessing
overall cardiovascular risk and detecting complications. </span></p>
<p class=MsoNormal><span lang=EN-US>Patients seen at the Gate Clinic with blood
pressure above 140/90 mmHg should be referred to the outpatient department if
there is markedly or persistently raised blood pressure, hyperglycaemia,
proteinuria or alarming symptoms. </span></p>
<p class=MsoNormal><span lang=EN-US>Drug therapy combined with lifestyle
measures is recommended to achieve a target blood pressure of less than 140/90
mmHg. Choice of drugs depends on stage of hypertension at presentation,
compelling indications and presence of comorbid conditions. Once-daily
medications are preferred to improve adherence to drug therapy. Drug therapy
should be adjusted until target blood pressure is reached provided adherence is
satisfactory. Once blood pressure control is achieved, do not reduce medication
doses unless side-effects occur. </span></p>
<p class=MsoNormal><span lang=EN-US>Patients seen in Fajara should be
discharged to local care when they are stable. Patients in Keneba should
continue care at their Gate Clinic.</span></p>
<p class=MsoNormal><span lang=EN-US>This guideline has been updated to address
differences between Fajara and Keneba.</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Limitations </span></h3>
<h2><span lang=EN-US style='font-size:11.0pt;font-weight:normal'>This guideline
does not address the emergency management of acute hypertensive emergencies.</span><span
lang=EN-US><br clear=all style='page-break-before:always'>
</span></h2>
<h2><span lang=EN-US style='font-size:11.0pt'>P</span><span lang=EN-US>resenting
symptoms and signs</span></h2>
<p class=MsoNormal><span lang=EN-US>Hypertension is generally accepted as a
systolic blood pressure &#8805; 140 mmHg, diastolic blood pressure &#8805; 90
mmHg or use of antihypertensive medication prescribed by a qualified clinician.</span></p>
<h3><span lang=EN-US>Symptoms:</span></h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Uncomplicated essential hypertension is usually
asymptomatic.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Secondary hypertension may present with symptoms
of underlying disease condition.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Facial puffiness, nocturia, or passage of dark
or frothy urine is suggestive of renal disease</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Excessive sweating, palpitations and heat
intolerance suggests hyperthyroidism</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Episodes of palpitations, dizziness, headache
and sweating may occur in phaeochromocytoma</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Suspect secondary hypertension in patients newly
diagnosed with hypertension who are younger than 30 years.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Features of some common complications:</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Dyspnea on exertion, difficulty lying flat
(orthopnea), bilateral leg swelling in heart failure</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Slurred speech, limb weakness in stroke</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Headache, abnormal behavior, altered
consciousness, seizures in hypertensive encephalopathy</span></p>
<h3><span lang=EN-US>Signs:</span></h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>In earlier stages, no other presenting signs apart from raised
blood pressure in essential hypertension</p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Secondary hypertension may present with signs of
the underlying condition</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Hypertension may also present with signs of
complications such as stroke, encephalopathy, renal failure or heart failure.</span></p>
<h2 style='margin-bottom:6.0pt'><span lang=EN-US>Examination findings</span></h2>
<p class=MsoListParagraph style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Elevated blood pressure</span></p>
<h3><span lang=EN-US>Important things to look for in OPD:</span><span
lang=EN-US> </span></h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Features of long-standing hypertension: </span>thickened
arterial walls, heaving apex beat, loud aortic component of second heart sound,
retinal changes on fundoscopy.</p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Radiofemoral delay: Coarctation of the aorta</p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Renal bruit: Renal artery stenosis</p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Ballotable kidneys: Polycystic kidney disease</p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Pallor, peripheral oedema, facial oedema: Chronic kidney disease</p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2 style='margin-bottom:6.0pt'><span lang=EN-US>Differential diagnoses</span></h2>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Renal disease</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Vascular disorders</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Renal artery stenosis</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Coarctation of the aorta</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Endocrine disorders </span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Hypothyroidism </span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Hyperthyroidism</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Phaeochromocytoma</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Adrenal hypersecretion (Cushing syndrome, Conn
syndrome)</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Drugs:</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Steroids (including oral contraceptive pills)</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Non-steroidal anti-inflammatory drugs (NSAIDs)</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Hypertensive disorders of pregnancy</span></p>
<h2><span lang=EN-US>Investigations</span></h2>
<h3>To exclude a secondary cause </h3>
<p class=MsoNormal>For all patients under 30 years and others where there are
signs to suggest another problem:</p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Urinalysis<b> </b></span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span>Proteinuria of 2+ or more suggests renal cause</p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span>Haematuria may indicate nephritic syndrome</p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Serum Electrolytes, Urea &amp; Creatinine</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Elevated creatinine suggests renal involvement</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Derangements in potassium and bicarbonate may
point to an adrenal problem</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Full blood count</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Chronic kidney disease causes anaemia
(microcytic or normocytic)</span></p>
<h3>To assess other important cardiovascular risk factors</h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Fasting plasma glucose</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Fasting Serum Cholesterol (total and HDL only) –
these should only be done if the patient does not already have a history of
ischaemic heart disease or stroke. For such patients – estimate their
cardiovascular risk using QRISK2 <a href="https://qrisk.org/2017/">https://qrisk.org/2017/</a>
</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>If the risk is &gt; 10%, do not check the
cholesterol, but advise the patient to start taking a statin anyway. </span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>If the risk is &lt; 5%, they will not need to
take a statin whatever their cholesterol level. </span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Only check the cholesterol for those patients
with risk of 5-10%, then recalculate the risk once the result is available and
recommend statins for those with a risk of 10% or more. </span></p>
<h3>To detect subclinical complications</h3>
<p class=MsoListParagraph style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>ECG</span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2><span lang=EN-US>Management in Gate Clinic</span></h2>
<h2><span lang=EN-US style='font-size:11.0pt;font-weight:normal'>At the first
visit if the BP is &gt; 140/90, request urine dipstick and test blood glucose.</span></h2>
<p class=MsoNormal><span lang=EN-US>Refer to a doctor if:</span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>BP is greater than 180 mmHg (systolic) or 110
mmHg (diastolic)</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>protein in the urine</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>blood glucose is raised (fasting &gt; 6.9
mmol/l, random &gt; 11.1 mmol/l)</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>any complaints of shortness of breath, chest
pain, severe headaches or visual disturbance.</span></p>
<p class=MsoNormal><span lang=EN-US>Otherwise, advise the patient to:</span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>reduce the salt in their diet</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>lose weight if they are overweight</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>increase their regular exercise.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Increase intake of fruits, vegetables and nuts</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Stop smoking and limit alcohol (if applicable) </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Ask them to return in 1-2 days. </span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:72.0pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:"Courier New"'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
</span></span><span lang=EN-US>Repeat BP at the return visit. If it is greater
than 140/90 mmHg on a second occasion, refer to the doctor.</span></p>
<h2><span lang=EN-US>Management in OPD</span></h2>
<p class=MsoNormal><span lang=EN-US>The target blood pressure for treating
hypertension is a systolic blood pressure of 140mmHg <b>and </b>a diastolic
blood pressure of 90 mmHg. Drugs given once daily are preferred to improve
adherence to treatment. Counsel patients adequately on the benefits of their
treatment, side-effects and the risks of non-adherence. Remind them of the
importance of avoiding salt intake and emphasise the need for life-long
therapy.</span></p>
<p class=MsoNormal><span lang=EN-US>Generally, for patients with systolic blood
pressure less than 160 mmHg <b>and </b>diastolic blood pressure less than 100
mmHg, it is preferable to start with a <b>single drug</b>.</span></p>
<p class=MsoListParagraphCxSpFirst style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.15pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If the patients is not diabetic and has no signs
of kidney disease, start with a thiazide at low dose (Bendroflumethiazide 2.5
mg OD)</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-top:0cm;margin-right:0cm;
margin-bottom:0cm;margin-left:36.15pt;margin-bottom:.0001pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If the patient is diabetic without signs of
kidney disease, start with a calcium channel blocker at low dose (Amlodipine 5 mg
OD)</span></p>
<p class=MsoListParagraphCxSpLast style='margin-left:36.15pt;text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If the patient has features of chronic kidney disease,
place them on an ACE inhibitor (usually Ramipril 2.5 mg OD) at the lowest
effective dose after excluding contraindications. </span></p>
<p class=MsoNormal><span lang=EN-US>If blood pressure is still &gt;140/90 mmHg
at subsequent clinic visits:</span></p>
<p class=MsoListParagraphCxSpFirst style='margin-bottom:0cm;margin-bottom:.0001pt;
text-indent:-18.0pt'><span lang=EN-US style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Enquire about adherence to drug therapy and
lifestyle changes. Patients should be encouraged to bring their leftover/empty
medication containers on clinic visits</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0cm;margin-bottom:
.0001pt;text-indent:-18.0pt'><span lang=EN-US style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If adherence appears satisfactory, increase the
dose of the medication gradually with each clinic visit until target blood
pressure is reached or maximum dose of the drug is achieved.</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0cm;margin-bottom:
.0001pt;text-indent:-18.0pt'><span lang=EN-US style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If blood pressure is not at target despite
maximum dose of the drug, add a second antihypertensive from a different class
to the patient’s treatment (see flow chart below).</span></p>
<p class=MsoListParagraphCxSpMiddle style='margin-bottom:0cm;margin-bottom:
.0001pt;text-indent:-18.0pt'><span lang=EN-US style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Gradually increase this second drug until target
blood pressure is reached or maximum dose of the drug is achieved. </span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Do not reduce drug doses after target blood
pressure is attained unless patient has symptoms and signs of hypotension.</span></p>
<p class=MsoNormal><span lang=EN-US>For patients who present initially with
systolic blood pressure &#8805; 160 mmHg  or diastolic blood pressure &#8805;
100 mmHg, or patients whose blood pressure is not at target despite maximum
dose of the drug, <b>combination therapy </b>is recommended.</span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>For patients without diabetes mellitus or kidney
disease, start with a combination of a calcium channel blocker and a thiazide
diuretic (Amlodipine 5 mg OD and Bendroflumethiazide 2.5 mg OD).</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>For patients with diabetes mellitus, start with
a calcium channel blocker and an ACE inhibitor.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>For patients with kidney disease, place the
patient on a combination of an ACE inhibitor with either a calcium channel
blocker or a thiazide diuretic.</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Gradually increase the doses of individual drugs
at subsequent clinic visits until either target blood pressure is achieved or
the maximum doses of <b>both</b> drugs are reached. </span></p>
<p class=MsoNormal><span lang=EN-US>Compelling indications are special
conditions in which particular classes of hypertension drugs must be
prescribed. </span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Pregnancy: alpha-methyldopa, nifedipine, labetalol
or hydralazine</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Chronic kidney disease: ACE inhibitors</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Heart failure: ACE inhibitors + spironolactone +
diuretics (+ beta blocker when stable)</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Previous stroke: ACE inhibitors or thiazide
diuretic.</span></p>
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
<span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal>
<div class="tableCont">
  <table cellpadding=0 cellspacing=0 align=left>
 <tr>
  <td width=0 height=1></td>
 </tr>
 <tr>
  <td></td>
  <td><img width=685 height=676
  src="htn_image001.png"></td>
 </tr>
</table>
</div>
<span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<br clear=ALL>
<p class=MsoNormal><span lang=EN-US>Patients who do not have adequate control
after following this flow chart:</span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Those who are not at target despite a combination
of two drugs at maximum doses should have a third drug from an unused class
added (ACEI +CCB +Thiazide).</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Those who remain uncontrolled at maximal doses
of three drugs should be re-evaluated for secondary hypertension. A fourth drug
(spironolactone or a beta blocker) can be added. </span></p>
<span lang=EN-US style='font-size:10.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
lang=EN-US style='font-size:10.0pt'>&nbsp;</span></p>
<h3><span lang=EN-US>Considerations for individual drugs</span></h3>
<div class="tableCont">
  <table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=132 valign=top style='width:99.0pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Drug group</span></b></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Indications</span></b></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Contraindications and monitoring</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Thiazides</span></b></p>
  <p class=MsoNormal><i><span lang=EN-US>Bendroflumethiazide 2.5 mg OD</span></i></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>First line if no DM or heart failure.</span></p>
  <p class=MsoNormal><span lang=EN-US>Add to ACEi / CCB to improve control.</span></p>
  <p class=MsoNormal><span lang=EN-US>Do not increase dose – it increases the
  side effects without improving effectiveness.</span></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>Ensure that patients are counseled
  regarding risks of diuretic use and necessity to omit medications when having
  an intercurrent diarrhoeal illness.</span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Calcium channel blockers (CCB)</span></b></p>
  <p class=MsoNormal><i><span lang=EN-US>Amlodipine 5-10 mg OD</span></i></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>First line for co-existing DM. </span></p>
  <p class=MsoNormal><span lang=EN-US>Second line in pregnancy (but use
  nifedipine not amlodipine).</span></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>ACE inhibitors (ACEi)</span></b></p>
  <p class=MsoNormal><i><span lang=EN-US>Ramipril 2.5-10 mg OD</span></i></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>First line for co-existing heart failure.</span></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>Check K and Creatinine one month after
  start of treatment and stop if creatinine rises by &gt; 30%.</span></p>
  <p class=MsoNormal><span lang=EN-US>ACE inhibitors can cause a chronic dry
  cough. All patients should watch out for angioedema.</span></p>
  <p class=MsoNormal><span lang=EN-US>Female patients on ACE inhibitors should
  be counseled on the danger of using them in pregnancy. </span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Spironolactone</span></b></p>
  <p class=MsoNormal><i><span lang=EN-US>25-100 mg OD</span></i></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>Fourth line for patients with
  uncontrolled BP despite being on 3 other medications.</span></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>Avoid if serum potassium is &gt; 4.5
  mmol/l.</span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Beta blockers</span></b></p>
  <p class=MsoNormal><i><span lang=EN-US>Bisoprolol 1.25-10 mg OD</span></i></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>Fourth line for stable heart failure or
  for patients with uncontrolled BP despite being on 3 other medications. </span></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=132 valign=top style='width:99.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Methyldopa</span></b></p>
  <p class=MsoNormal><span lang=EN-US>250 mg BD – 500 mg TDS</span></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>First line for pregnancy.</span></p>
  </td>
  <td width=222 valign=top style='width:166.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
<p class=MsoNormal><b><span lang=EN-US>For patients seen at Fajara, discharge
to local care once stable on medication</span></b><span lang=EN-US>. <br>
<b>For patients seen at Keneba, continue care at the Gate Clinic once stable on
medication.</b> </span></p>
<p class=MsoNormal><span lang=EN-US>Recommend patient remains on medication and
has annual blood tests. </span><span lang=EN-US><br clear=all style='page-break-before:
always'>
</span></p>
<h2><span lang=EN-US>Key Issues for Nursing care</span></h2>
<p class=MsoNormal><span lang=EN-US>How to measure blood pressure correctly:</span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The patient should be relaxed, comfortably
seated with back supported, legs uncrossed and measured arm supported at heart
level.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Radial or brachial pulse should be assessed for
rhythm<b>.</b></span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If irregular, do not use the automatic blood
pressure machine. Use a manual sphygmomanometer instead.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>An appropriate cuff size should be selected and
applied mid-arm (about 2 cm above the elbow)</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>The patient should not speak during blood
pressure measurement.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Measure the blood pressure in both arms. If the
difference is more than 20 mmHg between both arms, document the arm with higher
reading and use this arm for all future measurements in the patient.</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If the blood pressure reading is higher than
140/90 mmHg, repeat the measurement. If second measurement is significantly
different, take a third reading and keep the lower of the last two values.</span></p>
<h2><span lang=EN-US>References</span></h2>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Flack JM, Sica DA,
Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr et al. Management of High Blood
Pressure in Blacks: An Update of the International Society on Hypertension in
Blacks Consensus Statement. Hypertension. 2010;56:780-800.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>National Institute
for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and
management. NICE; 2011. Available from: </span><span lang=EN-US><a
href="http://www.nice.org.uk/guidance/cg127/chapter/1-Guidance"><span
style='font-size:10.0pt'>www.nice.org.uk/guidance/cg127/chapter/1-Guidance</span></a></span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>James PA, Oparil
S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J.2014 evidence-based
guideline for the management of high blood pressure in adults: report from the
panel members appointed to the Eighth Joint National Committee (JNC 8).JAMA.
2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Armstrong C; Joint
National Committee.JNC8 guidelines for the management of hypertension in
adults.Am Fam Physician. 2014 Oct 1;90(7):503-4.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Williams SK,
Ravenell J, Seyedali S, Nayef S, Ogedegbe G. Hypertension Treatment in Blacks:
Discussion of the U.S. Clinical Practice Guidelines. Prog Cardiovasc Dis. 2016
Nov-Dec; 59(3): 282–288.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>World Health
Organization (WHO). Raised blood pressure. Geneva: WHO; 2018. Available from: </span><span
lang=EN-US><a
href="http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/"><span
style='font-size:10.0pt'>http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/</span></a></span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Alexander MR.
Hypertension. Medscape; 2018. Available from: </span><span lang=EN-US><a
href="https://emedicine.medscape.com/article/241381"><span style='font-size:
10.0pt'>https://emedicine.medscape.com/article/241381</span></a></span></p>
<span class=MsoHyperlink><span lang=EN-US style='font-size:11.0pt;font-family:
"Arial","sans-serif"'><br clear=all style='page-break-before:always'>
</span></span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
class=MsoHyperlink><span lang=EN-US><span style='text-decoration:none'>&nbsp;</span></span></span></p>
<div class="tableCont">
  <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Written by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Name: Fatai Momodu Akemokwe</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Date: 22 May 2018</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Reviewed by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Name: Karen Forrest</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Date: 25 June 2018</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Version:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Change history:</span></b></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Review due date:</span></b></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>1.0</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>New document</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>2.0</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Rewritten on new template and to address differences between
  Fajara and Keneba</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>31 July 2020</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>2.1</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Executive summary added</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>31 July 2020</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Review Comments (<i>if applicable)</i></span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>&nbsp;</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>&nbsp;</span></b></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
</div>
</div><!-- /content -->
<div data-role="panel" data-position="right" data-display="overlay" data-position-fixed="true" data-theme="b" id="leftpanel1">
	<a href="#" data-rel="close" data-theme="b" class="ui-btn ui-corner-all ui-shadow ui-btn-a ui-icon-delete ui-btn-icon-notext ui-btn-right">Close</a>
  <h1>About this app</h1>
  <div>
    This app is designed to provide doctors and nurses with quick access to the clinical guidelines of the Clinical Services Department of the MRC Unit The Gambia at LSHTM. <br>Users will be notified of updates via departmental email. <br>For feedback or support, email fakemokwe@mrc.gm
  </div>
</div>
</div>
<div data-role="footer" data-tap-toggle="false" data-id="persistent-footer" data-position="fixed" data-theme="a">
  <a href="index.html" class="ui-btn ui-corner-all ui-btn-inline ui-mini footer-button-left ui-btn-icon-left ui-icon-home">Home</a>
  <a href="#" onclick="topFunction()" id="myBtn" class="ui-btn ui-corner-all ui-btn-inline ui-mini footer-button-right ui-btn-icon-right ui-icon-carat-u">Top</a>  
</div>
</body>
</html>
